Catalio Capital Management
New York–based investment firm focused on the full lifecycle of healthcare and life sciences investing across private, public and credit markets. Catalio invests across the capital structure and stages, provides capital through private equity, structured opportunities, public equities and co-investments, and works with portfolio companies from inception to exit. The firm emphasizes scientific and clinical due diligence through a network of Venture Partners.
Catalio Capital Management
New York, New York, United States, North America
Services
Capital provision across strategies
Provides capital and invests across multiple strategies including Private Equity, Structured Opportunities, Public Equities and Co-Investments across the capital structure.
Scientific and clinical due diligence
Proprietary expert network of Venture Partners (scientist-entrepreneurs and Nobel/Breakthrough prize winners) that provide rigorous scientific and clinical due diligence and early technical assessment of biomedical technologies.
Strategic guidance and operational support
Works closely with portfolio companies to build and grow businesses from inception to exit, offering strategic guidance on clinical, regulatory and commercial matters.
Network and commercialization support
Provides access to a network of industry leaders, founders and scientific advisors to inform commercialization, partnerships, and market entry strategies.
Capital provision across strategies
Provides capital and invests across multiple strategies including Private Equity, Structured Opportunities, Public Equities and Co-Investments across the capital structure.
Scientific and clinical due diligence
Proprietary expert network of Venture Partners (scientist-entrepreneurs and Nobel/Breakthrough prize winners) that provide rigorous scientific and clinical due diligence and early technical assessment of biomedical technologies.
Strategic guidance and operational support
Works closely with portfolio companies to build and grow businesses from inception to exit, offering strategic guidance on clinical, regulatory and commercial matters.
Network and commercialization support
Provides access to a network of industry leaders, founders and scientific advisors to inform commercialization, partnerships, and market entry strategies.
Portfolio
Clinical-stage drug development company in-licensing mature, de-risked assets from Asia. Lead asset: Phase 3-ready EGFR inhibitor for non-small cell lung cancer. IPO in 2024 (Catalio portfolio).
#Drugs
Clinical-stage radiopharmaceutical company leveraging 212Pb as a radioisotope; developing a pipeline including a potential best-in-class prostate cancer program.
#Drugs (radiopharmaceuticals)
Preclinical-stage T-cell therapeutics for solid tumors; platform combines CD4+ and CD8+ targeting. Founded by Catalio Venture Partner Dr. Phil Greenberg. Backed by a scientific advisory board including Nobel Laureate Jim Allison.
#Drugs (cell therapy)
Clinical-stage company developing CLDN1-targeting biologics and ADCs for epithelial cancers; two clinic-ready CLDN1 ADCs with differing payloads.
#Drugs (oncology biologics/ADCs)
Early-stage drug discovery company combining DNA-encoded libraries and machine learning to accelerate hit discovery across oncology, inflammation, musculoskeletal and cardiovascular targets.
#Drugs (drug discovery platform)
AI-driven platform for monitoring patient acuity and augmenting clinical decision-making in hospitals; positions health systems for value-based care.
#Other (digital health/clinical AI)
Clinical-stage drug development company in-licensing mature, de-risked assets from Asia. Lead asset: Phase 3-ready EGFR inhibitor for non-small cell lung cancer. IPO in 2024 (Catalio portfolio).
#Drugs
Clinical-stage radiopharmaceutical company leveraging 212Pb as a radioisotope; developing a pipeline including a potential best-in-class prostate cancer program.
#Drugs (radiopharmaceuticals)
Preclinical-stage T-cell therapeutics for solid tumors; platform combines CD4+ and CD8+ targeting. Founded by Catalio Venture Partner Dr. Phil Greenberg. Backed by a scientific advisory board including Nobel Laureate Jim Allison.
#Drugs (cell therapy)
Clinical-stage company developing CLDN1-targeting biologics and ADCs for epithelial cancers; two clinic-ready CLDN1 ADCs with differing payloads.
#Drugs (oncology biologics/ADCs)
Early-stage drug discovery company combining DNA-encoded libraries and machine learning to accelerate hit discovery across oncology, inflammation, musculoskeletal and cardiovascular targets.
#Drugs (drug discovery platform)
AI-driven platform for monitoring patient acuity and augmenting clinical decision-making in hospitals; positions health systems for value-based care.
#Other (digital health/clinical AI)